Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation - Schedule of Stock-based Compensation Expense Classified in Research and Development Expenses (Details)

v3.21.1
Stock-Based Compensation - Schedule of Stock-based Compensation Expense Classified in Research and Development Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Stock-based compensation expense $ 1,436 $ 344
General and Administrative Expenses [Member]    
Stock-based compensation expense 1,124 243
Research and Development Expenses [Member]    
Stock-based compensation expense 110 67
Research and Development Expenses [Member] | Lucid Diagnostics Inc [Member]    
Stock-based compensation expense 805 16
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expenses [Member]    
Stock-based compensation expense 789
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expenses [Member]    
Stock-based compensation expense 13 13
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expenses [Member]    
Stock-based compensation expense $ 3 $ 3